Soluble CD163 and prediction of disease. “Methods of Prognosis”.

Ruth Frikke-Schmidt; Anne  Tybjærg-Hansen

Soluble CD163 and prediction of disease. “Methods of Prognosis”.

Ruth Frikke-Schmidt (Opfinder), Anne Tybjærg-Hansen (Opfinder)

Abstract

The present invention relates to the use of soluble CD163 as a prognostic marker for the assessment of the risk for contracting a disorder, in particular for contracting diabetes and/or a liver disorder. The invention also relates to the use of CD163 as a prognostic marker for assessing lifetime expectancy.

Originalsprog	Engelsk
IPC	G01N33/50,DK2010050260
Patentnummer	WO2011044904A2
Land/Område	Danmark
Status	Udgivet - 21 apr. 2011
Udgivet eksternt	Ja

Adgang til dokumentet

https://worldwide.espacenet.com/patent/search/family/043480438/publication/WO2011044904A2?q=DK2010050260

Citationsformater

@misc{1bab8462ebf546e8bb52be6da1688079,

title = "Soluble CD163 and prediction of disease. “Methods of Prognosis”.",

abstract = "The present invention relates to the use of soluble CD163 as a prognostic marker for the assessment of the risk for contracting a disorder, in particular for contracting diabetes and/or a liver disorder. The invention also relates to the use of CD163 as a prognostic marker for assessing lifetime expectancy.",

author = "Ruth Frikke-Schmidt and Anne Tybj{\ae}rg-Hansen",

year = "2011",

month = apr,

day = "21",

language = "English",

type = "Patent",

note = "WO2011044904A2; G01N33/50,DK2010050260",

}

TY - PAT

T1 - Soluble CD163 and prediction of disease. “Methods of Prognosis”.

AU - Frikke-Schmidt, Ruth

AU - Tybjærg-Hansen, Anne

PY - 2011/4/21

Y1 - 2011/4/21

N2 - The present invention relates to the use of soluble CD163 as a prognostic marker for the assessment of the risk for contracting a disorder, in particular for contracting diabetes and/or a liver disorder. The invention also relates to the use of CD163 as a prognostic marker for assessing lifetime expectancy.

AB - The present invention relates to the use of soluble CD163 as a prognostic marker for the assessment of the risk for contracting a disorder, in particular for contracting diabetes and/or a liver disorder. The invention also relates to the use of CD163 as a prognostic marker for assessing lifetime expectancy.

M3 - Patent

M1 - WO2011044904A2

ER -